- Conditions
- Prostate Cancer Metastatic Disease
- Interventions
- Hypocaloric anti-inflammatory diet
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
Institution Directory
Clinical trials at UCLA Health
Sites in Los Angeles, CA
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1104
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 973–984 of 1,104 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Live official records
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409
Site status not listed — check the official record
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2033
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
NCT03311503
Status at this site: Recruiting
- Conditions
- Severe Combined Immunodeficiency, X Linked, Gene Therapy
- Interventions
- autologous CD34+ cell transduced with G2SCID vector
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 0 Years to 5 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986
Site status not listed — check the official record
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
- Interventions
- Olaparib 300mg tablets
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 81
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
- Conditions
- Ischemic Stroke
- Interventions
- Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management
- Device · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 34 more
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
NCT06617312
Status at this site: Recruiting
- Conditions
- Smoking Cessation, Tobacco Use Disorder
- Interventions
- Cytisinicline, Placebo Oral Capsule
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Urinary Biomarkers of OI Pathobiology
NCT02531087
Site status not listed — check the official record
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Omaha, Nebraska • New York, New York + 3 more
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
NCT05525507
Status at this site: Recruiting
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Interventions
- Conditioning and Stem cell infusion
- Combination Product
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Immunological Tolerance in Patients With Mismatched Kidney Transplants
NCT05806749
Site status not listed — check the official record
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Interventions
- Donor CD34+, CD3+. and belumosudil
- Combination Product
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326
Site status not listed — check the official record
- Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Interventions
- Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Pragmatic Trial of Psilocybin Therapy in Palliative Care
NCT05403086
Status at this site: Recruiting
- Conditions
- Demoralization
- Interventions
- Psilocybin, Ketamine
- Drug
- Lead sponsor
- Charles S. Grob, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
NCT01697527
Site status not listed — check the official record
- Conditions
- Malignant Neoplasm
- Interventions
- aldesleukin, fludarabine phosphate, cyclophosphamide, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, fludeoxyglucose F 18, positron emission tomography
- Biological · Drug · Other + 2 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
About this UCLA Health institution page
- What this page lists
- ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, browse by condition, or browse by U.S. city.